TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04684693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser puncture and exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Exercise
Study: NCT03447886

Intervention type: OTHER
Intervention: Phone interview
Description: Collecting clinical and socio-demographic information.
Study: NCT01567826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care lipid therapy
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggressive lipid therapy
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Study: NCT00737737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS Contin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02815202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-034)
Study: NCT00700817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg once daily, subcutaneous (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg once daily, subcutaneous (under the skin) injection
Study: NCT03491553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) OAV Therapy
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) OAV Therapy
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)
Study: NCT05673863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Resilience Program
Description: The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
Study: NCT03506399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study: NCT01400776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
Study: NCT01951508

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: 60mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil
Description: 600mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125mg per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: per os
Study: NCT01755897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical hysterectomy + pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy + pelvic lymph node dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135-175 mg/m(2) intravenously (IV) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m(2) IV on day 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 35 mg/m(2) IV once a week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic RT
Description: IMRT
Study: NCT03698396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic Islet Cell Transplantation
Description: Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
Study: NCT00309595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Cordis SMART™ Nitinol Stent System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon
Description: balloon angioplasty
Study: NCT01284907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drops
Study: NCT00700817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Tablets, 100 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Tablets, 100 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Tablets, 100 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, minimum 1500 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, minimum 1500 mg daily
Study: NCT03506399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive
Description: Administered orally
Study: NCT04442919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor followed with Methoxyflurane
Description: patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
Study: NCT04442919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor followed with Morphine
Description: patients who received ticagrelor followed with intravenous morphine due to unstable angina
Study: NCT03158025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant tablets
Description: Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
Study: NCT04442919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor alone
Description: patients who received ticagrelor without any analgesia due to unstable angina
Study: NCT00534937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression wrapping
Description: Short-stretch compression wrap will be applied at least once a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexitouch compression pump
Description: In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
Study: NCT00787033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04554878
Description: Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
Study: NCT02937831

Intervention type: BIOLOGICAL
Intervention: RIXUBIS
Study: NCT01446068

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: Three caloric doses of high-fat meal (500, 1000, 1500 kcal)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
Study: NCT01959126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-reduction class
Description: Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
Study: NCT00812877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: Pulp capping agent, Mineral TrioxideAggregate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Pulp capping agent, Calcium Hydroxide
Study: NCT02329457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Description: varicella zoster vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: varicella zoster vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline placebo vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline placebo vaccine
Study: NCT04801563

Intervention type: OTHER
Group type: OTHER
Intervention: MDS and AlloHSCT
Description: Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
Study: NCT03720210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
Study: NCT00703911

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
Study: NCT04529382

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive testing (Bayley III, WPPSI III and WISC V)
Description: Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive testing (Bayley III, WPPSI III and WISC V)
Description: Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
Study: NCT02817334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
Study: NCT01908296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: Oral
Study: NCT03607708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
Study: NCT01111526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m\^2 IV; DL 1: 2.5 mg/m\^2 IV; DL 2: 5 mg/m\^2 IV; DL 3: 7.5 mg/m\^2 IV; DL 4: 10 mg/m\^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks.
Study: NCT03108651

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case
Description: Motivational message will be administrated.
Study: NCT04991844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Intervention group participants met once a week, for 2.5 hours, over a period of six weeks for the HES workshops. The HES workshops followed a scripted curriculum that incorporated information from the USDA's MyPlateTM, and the USDA 2015-2020 dietary guidelines. Participants were also taught goal-setting, problem-solving through brainstorming, group support, self-assessment and management of dietary and physical activity patterns.
Study: NCT04176055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: haloperidol intervention
Study: NCT04480697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo
Study: NCT04051151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gameficiation
Description: Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
Study: NCT02622724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for investigational drug
Study: NCT03029650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transderm Scop®
Description: TDDS dosage is 1.5 mg/72 hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transderm Scop®
Description: TDDS dosage is 1.5 mg/72 hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous scopolamine hydrobromide
Description: 0.4 mg via intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous scopolamine hydrobromide
Description: 0.4 mg via intravenous injection
Study: NCT03785496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
Study: NCT02687230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-2163
Description: MVT-2163 is administered intravenously as a PET imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-2163
Description: MVT-2163 is administered intravenously as a PET imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-2163
Description: MVT-2163 is administered intravenously as a PET imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
Study: NCT03801525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: * B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: * B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form
Study: NCT03181763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given day after startle assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Participant will receive 100 mg MDMA one day after startle assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic startle
Description: Startle assessment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acoustic startle
Description: Startle assessment
Study: NCT04424641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Description: GEN1044 will be administered intravenously in cycles of 21 days.
Study: NCT00597038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib and Dacarbazine (DTIC)
Description: Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib and Dacarbazine (DTIC)
Description: Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2.
Study: NCT00221767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brindley technique (bladder system)
Description: Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
Study: NCT03201549

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral fructose challenge
Description: Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
Study: NCT02351648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a transitional care model
Description: Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients
Study: NCT00700817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, minimum 1500 mg daily
Study: NCT02351648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients receive usual standard of care from the internal medicine team